Peptides for Macular Degeneration: Mitochondrial Protection, Anti-VEGF Peptide Fragments, and Retinal Neuroprotection

How peptide Targets Peptides for Macular Degeneration & Retinal Health

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 50, affecting approximately 200 million people worldwide. The disease exists in two forms: dry AMD (geographic atrophy), which accounts for 85-90% of cases and involves progressive degeneration of the retinal pigment epithelium (RPE) and photoreceptors, and wet AMD (neovascular), where abnormal blood vessel growth beneath the retina causes rapid vision loss. While anti-VEGF injections (ranibizumab, aflibercept, bevacizumab) have transformed wet AMD treatment, dry AMD has historically lacked effective therapies. Mitochondrial dysfunction, oxidative stress, complement dysregulation, and impaired autophagy in RPE cells are now recognized as central drivers of dry AMD pathogenesis, creating a rationale for peptide-based interventions that target these mechanisms.

SS-31 (elamipretide, also known as Bendavia or MTP-131) is the most clinically advanced peptide for macular degeneration. This mitochondria-targeted tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) concentrates in the inner mitochondrial membrane where it binds cardiolipin, stabilizes cristae structure, and restores electron transport chain efficiency. In the retina, RPE cells are among the most metabolically active cells in the body, and their mitochondria deteriorate significantly with age and AMD progression. Stealth BioTherapeutics conducted the ReCLAIM and ReCLAIM-2 Phase 2 clinical trials evaluating subcutaneous elamipretide injections in patients with dry AMD and geographic atrophy. ReCLAIM demonstrated improvements in low-luminance visual acuity and dark adaptation — functional measures reflecting RPE and photoreceptor health — though the primary endpoint results were mixed. The drug received Fast Track designation from the FDA for the treatment of dry AMD associated with mitochondrial dysfunction. However, later-stage trial results have been variable, and elamipretide has not yet achieved regulatory approval for AMD. The rationale remains compelling: restoring mitochondrial function in RPE cells could slow the degenerative cascade before irreversible photoreceptor loss occurs.

Humanin is a 24-amino-acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA. It has demonstrated significant cytoprotective effects in retinal cells through multiple preclinical studies. Humanin protects RPE cells from oxidative stress-induced apoptosis, reduces amyloid-beta toxicity (drusen contain amyloid-beta deposits), and activates the STAT3 signaling pathway to promote cell survival. In mouse models of AMD and retinal degeneration, humanin and its more potent analogue HNG (S14G-humanin) preserved photoreceptor function and reduced RPE cell death. Humanin levels decline with age in both systemic circulation and retinal tissue, correlating with AMD risk. While humanin remains at the preclinical stage for ocular applications and faces delivery challenges (short half-life, need for intravitreal or systemic administration), it represents a novel approach to retinal protection through endogenous mitochondrial signaling. Anti-VEGF peptide fragments and mimetics are also being explored as alternatives to full monoclonal antibodies for wet AMD, potentially offering smaller molecular size for better tissue penetration, reduced manufacturing costs, and alternative delivery routes including topical eye drops — though none have yet matched the clinical efficacy of established anti-VEGF biologics. GHK-Cu, while not directly studied in AMD, has documented roles in tissue remodeling, anti-inflammatory signaling, and antioxidant gene activation (including SOD and glutathione system upregulation) that are mechanistically relevant to retinal oxidative stress.